Immunoglobulin Market Expected to Reach $25.6 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Immunoglobulin Market," The immunoglobulin market was valued at $13.5 billion in 2022, and is estimated to reach $25.6 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. Immunoglobulins, also known as antibodies, are crucial proteins produced by the immune system to defend the body against infections and diseases. These Y-shaped molecules recognize and bind to specific foreign substances, such as viruses or bacteria, marking them for destruction by other immune cells. Comprising various classes such as IgG, IgA, IgM, IgD, and IgE, immunoglobulins play diverse roles in immune responses. IgG, the most abundant type, provides long-term immunity, while IgM is involved in initial defense. IgA safeguards mucosal surfaces, IgD aids B-cell development, and IgE is associated with allergic responses. Together, immunoglobulins form a vital defense mechanism for the body's overall health. 

The immunoglobulin industry is experiencing substantial growth due to the increase in incidence of chronic diseases such as myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, and Guillain-Barre syndrome, among others. Additionally, heightened awareness among healthcare professionals and the general public regarding the efficacy of immunoglobulin in treating chronic conditions is driving market expansion. As awareness grows, there is a rising acceptance of immunoglobulin therapies as effective treatments for various ailments, contributing to the market's sustained momentum. 

Furthermore, the growth of the immunoglobulin market trends is propelled by the increasing implementation of key strategies among major industry players, including service launches, acquisitions, and product approval. For instance, CSL Behring, a global biotherapeutics leader, received orphan-drug exclusivity from the U.S. Food and Drug Administration (FDA) for Hizentra for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. Additionally, Grifols, a global leader in plasma-derived medicines, completes the acquisition of Biotest in April 2022. This strategic and transformational transaction will help to accelerate growth and innovation. These initiatives by key players play a pivotal role in driving the sustained growth of the immunoglobulin industry during the forecast period. 

However, the growth of the immunoglobulin market is expected to encounter obstacles due to intricate manufacturing processes and dependence on a consistent supply of plasma or alternative sources for antibody production. Additionally, the high treatment costs pose a significant barrier, limiting accessibility for patients and potentially hindering market expansion. 

On the basis of application, the immunoglobulin market analysis is categorised into primary immunodeficiency disease, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, Guillain-Barre syndrome and others. The primary immunodeficiency disease segment accounted for the largest share in terms of revenue in 2022 and is expected to exhibit the fastest CAGR during the forecast period. This growth is attributed to several factors, including an increasing prevalence of primary immunodeficiency disorders, heightened awareness leading to early diagnosis, and advancements in immunoglobulin therapies. As these conditions become better understood and diagnostic capabilities improve, there is a rising demand for therapeutic interventions such as immunoglobulin treatments. 

On the basis of mode of delivery, the market is segmented into intravenous, subcutaneous and intramuscular. The intravenous segments accounted for the largest share in terms of revenue in 2022 and is expected to maintain its lead during the forecast period This is primarily due to the effectiveness and established use of intravenous administration in various therapeutic applications. Intravenous delivery ensures rapid and precise delivery of medications, including immunoglobulins, directly into the bloodstream, enhancing bioavailability and therapeutic outcomes. However, the subcutaneous segment is expected to register the fastest CAGR during the immunoglobulin market forecast period. This growth can be attributed to several factors, including advancements in subcutaneous delivery technologies, increased patient preference for at-home treatments, and the development of more convenient and user-friendly administration methods. 

On the basis of distribution channel, the market is classified into hospital pharmacy, drug stores & retail pharmacy and others. The hospital pharmacy segment accounted for the largest share in terms of revenue in 2022 and is expected to maintain its lead during the forecast period owing to several factors, including the central role of hospitals in acute and chronic disease management, the availability of comprehensive healthcare services, and the high demand for immunoglobulin therapies in hospital settings. However, the drug stores & retail pharmacy segment is expected to exhibit the fastest CAGR during the forecast period. This is primarily due to the expanding role of drug stores and retail pharmacies in providing accessible healthcare services and the increasing trend towards outpatient care. The convenience offered by retail outlets for obtaining immunoglobulin therapies, along with the potential for self-administration and at-home treatments, contributes to the segment's expected accelerated growth.  

On the basis of region, North America has the largest share in terms of revenue in 2022 and is expected to maintain its lead during the forecast period owing to several factors. The robust market position is attributed to the well-established healthcare infrastructure, high prevalence of target diseases necessitating immunoglobulin therapies, and a proactive approach towards advanced medical treatments. However, Asia-Pacific is expected to exhibit the fastest growth during the forecast period, owing to a large population base, increase in healthcare awareness, and rise in incidences of immunodeficiency disorders and autoimmune diseases contribute to a growing demand for immunoglobulin therapies in this region.  

Key Findings of the Study 

• On the basis of application, the primary immunodeficiency disease segment dominated the immunoglobulin market size in terms of revenue in 2022 and is anticipated to grow at fastest CAGR during the forecast period.  

• On the basis of mode of delivery, the intravenous segment dominated the immunoglobulin market share in terms of revenue in 2022. However, the subcutaneous segment is anticipated to grow at the fastest CAGR during the forecast period. 

• On the basis of distribution channel, the hospital pharmacy segment dominated the immunoglobulin market size in terms of revenue in 2022. However, the drug stores and retail pharmacies segment is anticipated to grow at the fastest CAGR during the forecast period. 

• Region wise, North America generated the largest immunoglobulin market share in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period